Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Brief Summary: The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.


Options:
A: Arm Label: Ketamine 0.1mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 0.2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 0.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 1.0mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Midazolam (Active Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.1mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.2mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.5mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 1.0mg | Intervention Type: DRUG; Name: Placebo Midazolam; Assigned to Arm(s): Midazolam (Active Placebo)
B: Arm Label: Intranasal Esketamine plus oral antidepressant; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Arm Label: Placebo plus oral antidepressant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Duloxetine (Oral Antidepressant), Drug: Escitalopram (Oral antidepressant), Drug: Sertraline (Oral Antidepressant), Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant) | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Duloxetine (Oral Antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Escitalopram (Oral antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Sertraline (Oral Antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant | Intervention Type: DRUG; Name: Venlafaxine Extended Release (XR) (Oral Antidepressant); Assigned to Arm(s): Intranasal Esketamine plus oral antidepressant, Placebo plus oral antidepressant
C: Arm Label: Intravenous Ketamine; Type: EXPERIMENTAL; Interventions: Drug: Intravenous Ketamine | Arm Label: Electroconvulsive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Electroconvulsive Therapy | Intervention Type: DRUG; Name: Intravenous Ketamine; Assigned to Arm(s): Intravenous Ketamine | Intervention Type: PROCEDURE; Name: Electroconvulsive Therapy; Assigned to Arm(s): Electroconvulsive Therapy
D: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): GLYX-13, 1 mg/kg, GLYX-13, 10 mg/kg, GLYX-13, 5 mg/kg, Normal Saline

Answer: B